X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/04/03/2856843/0/en/60-Degrees-Pharmaceuticals-to-Sponsor-Pilot-Study-of-Tafenoquine-for-Treatment-of-Canine-Babesiosis.html
https://www.globenewswire.com//news-release/2024/03/14/2846199/0/en/60-Degrees-Pharmaceuticals-Announces-Communication-from-the-FDA-of-Intention-to-Respond-to-Tafenoquine-Babesiosis-Trial-Protocol-Submission-in-April-2024.html
https://www.globenewswire.com//news-release/2024/02/20/2831741/0/en/60-Degrees-Pharmaceuticals-to-Sponsor-Pre-Clinical-Studies-of-Tafenoquine-Use-in-Candida-spp-Including-Candida-auris.html
https://www.globenewswire.com//news-release/2024/01/22/2812966/0/en/60-Degrees-Pharma-Plans-Pivotal-Babesiosis-Study-with-Tafenoquine-Following-Jan-17-FDA-Meeting.html
https://www.globenewswire.com/news-release/2023/12/26/2801070/0/en/60-Degrees-Pharma-Announces-IRB-Approval-of-Phase-IIA-Study-to-Evaluate-Tafenoquine-for-Babesiosis-an-Emerging-Tick-Borne-Disease-Type-C-Meeting-Re-Scheduled-by-FDA-to-January-17-2.html
https://www.globenewswire.com//news-release/2023/11/15/2780915/0/en/60-Degrees-Pharma-Announces-Type-C-Meeting-with-FDA-to-Discuss-Development-of-Tafenoquine-for-Babesiosis-an-Emerging-Tick-Borne-Disease.html
https://www.globenewswire.com//news-release/2023/10/12/2759672/0/en/60-Degrees-Pharmaceuticals-Suspends-Phase-IIB-Study-of-Tafenoquine-for-COVID-19-Pivots-to-Refocus-on-Commercialization-of-Treatments-for-Malaria-and-Tick-Borne-Diseases.html
https://www.globenewswire.com//news-release/2023/08/22/2729386/0/en/60-Degrees-Pharmaceuticals-Receives-Additional-U-S-Patent-Covering-Tafenoquine-for-Prevention-of-Plasmodium-Falciparum-Malaria.html
https://www.globenewswire.com/news-release/2023/08/15/2725374/0/en/60-Degrees-Pharmaceuticals-Registers-ACLR8-LR-a-Phase-IIB-Study-of-Tafenoquine-for-Treatment-of-COVID-19-on-ClinicalTrials-gov.html
https://www.globenewswire.com/news-release/2023/07/31/2714795/0/en/60-Degrees-Pharmaceuticals-Awarded-Canadian-Patent-Covering-Tafenoquine-for-Prevention-of-Malaria-in-Malaria-Naive-Subjects.html
https://www.globenewswire.com/news-release/2023/04/26/2654937/0/en/60-Degrees-Pharmaceuticals-Awarded-U-S-Patent-Covering-Tafenoquine-for-Treatment-of-COVID-19-and-Other-Lung-Infections.html
https://www.prnewswire.com/news-releases/positive-phase-ii-study-data-for-arakoda-tafenoquine-in-patients-with-mild-moderate-covid-19-disease-published-by-new-microbes-and-new-infections-larger-studies-planned-to-confirm-arakoda-accelerates-clinical-recovery-in-mild--301571551.html
https://www.nytimes.com/2022/03/14/health/malaria-children-tafenoquine.html
https://www.prnewswire.com/news-releases/arakoda-tafenoquine-clinical-safety-tolerability-confirmed-in-long-term-safety-study-results-published-in-tropical-medicine-and-infectious-disease-301428821.html
https://www.prnewswire.com/news-releases/data-safety-monitoring-board-recommends-completion-of-phase-ii-study-to-evaluate-the-efficacy-and-safety-of-arakoda-tafenoquine-for-treatment-of-mild-moderate-covid-19-disease-301398568.html
https://www.gsk.com/en-gb/media/press-releases/gsk-mmv-filing-for-kozenis-tafenoquine-in-paediatric-populations-with-plasmodium-vivax-malaria-accepted-by-australian-therapeutic-goods-administration/
https://www.businesswire.com/news/home/20200714005355/en/60-Degrees-Pharmaceuticals-Announces-Positive-Results-Cell
https://www.pharmaceutical-technology.com/news/brazil-p-vivax-tafenoquine/
https://www.raps.org/regulatory-focus/news-articles/2017/12/regulatory-explainer-everything-you-need-to-know-about-fdas-priority-review-vouchers
https://www.prnewswire.com/news-releases/us-food-and-drug-administration-approves-arakoda-tafenoquine-tablets-for-oral-use-first-preventative-antimalarial-approved-in-almost-two-decades-300694787.html
https://www.fiercebiotech.com/biotech/fda-adcomm-backs-gsk-s-one-shot-p-vivax-malaria-therapy
https://www.medpagetoday.com/infectiousdisease/generalinfectiousdisease/74008
Market Place
Share 
